NervGen Pharma Appoints Adam Rogers as Chief Executive Officer to Continue Leading the Company’s Growth and Execution of Its Mission in Spinal Cord Injury

Core Viewpoint - NervGen Pharma Corp. has appointed Dr. Adam Rogers as President and CEO, reflecting the Board's confidence in his leadership and vision for the company's future in neuroreparative therapeutics for spinal cord injury [1][2][3] Company Leadership - Dr. Rogers has been recognized for his decisive execution during his tenure as Interim CEO, including the successful Nasdaq listing and positioning of NVG-291 for late-stage development [2][3] - The Board believes Dr. Rogers embodies the leadership qualities necessary for advancing novel therapies, combining his experience as a physician and biotech executive [3] Company Mission and Vision - The company aims to transform the lives of individuals with spinal cord injuries by enabling the nervous system to repair itself, with NVG-291 as its lead therapeutic candidate [6][7] - Dr. Rogers emphasizes a mission-driven commitment to achieving meaningful progress for patients and communities affected by spinal cord injuries [3] Stock Options and Compensation - In connection with Dr. Rogers' appointment, the company granted 717,891 stock options, with specific vesting schedules and exercise prices [3] Background of Dr. Adam Rogers - Dr. Rogers has been on NervGen's Board since July 2022 and has a background in ophthalmology and biotechnology, having co-founded Hemera Biosciences and served as CEO [4][5]